Fairmount Funds Management LLC: ENLIVEN THERAPEUTICS INC (ELVN): Quarterly 13F Position History
As of Q1 2026, Fairmount Funds Management LLC reported 1,855,644 shares of ENLIVEN THERAPEUTICS INC (ELVN), worth $72.7M and representing 5.3% of its 13F equity book. Quarter-over-quarter share count change: 1,855,800 (-50.0%) . The position first appeared in Q1 2023 and has been disclosed across 13 13F-HR filings in Pactolio's tracked window.
- 1,855,644Shares Held (Latest Filing)
- $72.7MReported Market Value (Latest Filing)
- 5.3%Portfolio Weight (% of 13F Equity Book)
- 1,855,800Quarter-over-Quarter Share Change
- +$15.6MQuarter-over-Quarter Value Change
- 3,711,444Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 13 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,855,644 | 1,855,800 | -50.0% | $72.7M | 5.3% | $39.2 |
| Q4 2025 | 3,711,444 | 0 | — | $57.2M | 4.4% | $15.4 |
| Q3 2025 | 3,711,444 | 0 | — | $76.0M | 6.8% | $20.5 |
| Q2 2025 | 3,711,444 | +508,646 | +15.9% | $74.5M | 9.6% | $20.1 |
| Q1 2025 | 3,202,798 | 0 | — | $63.0M | 9.8% | $19.7 |
| Q4 2024 | 3,202,798 | 0 | — | $72.1M | 7.2% | $22.5 |
| Q3 2024 | 3,202,798 | 0 | — | $81.8M | 6.6% | $25.5 |
| Q2 2024 | 3,202,798 | 0 | — | $74.8M | 8.5% | $23.4 |
| Q1 2024 | 3,202,798 | +1,071,429 | +50.3% | $56.3M | 6.1% | $17.6 |
| Q4 2023 | 2,131,369 | 0 | — | $29.5M | 3.1% | $13.8 |
| Q3 2023 | 2,131,369 | +6,744 | +0.3% | $29.1M | 3.5% | $13.7 |
| Q2 2023 | 2,124,625 | +199,687 | +10.4% | $43.4M | 6.1% | $20.4 |
| Q1 2023 | 1,924,938 | — | — | $42.2M | 7.2% | $21.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Fairmount Funds Management LLC first disclose a ELVN position in 13F-HR filings?
Fairmount Funds Management LLC first reported ENLIVEN THERAPEUTICS INC (ELVN) on its 13F-HR filing for the period ending 2023-03-31 (Q1 2023). The position has appeared on 13 reported quarters within Pactolio's tracked window.
What was Fairmount Funds Management LLC's most recent quarter-over-quarter share-count change in ELVN?
Between Q4 2025 and Q1 2026, Fairmount Funds Management LLC reduced its ELVN position by 1,855,800 shares (-50.0%), leaving 1,855,644 shares at a market value of $72.7M.
Does the implied price-per-share represent Fairmount Funds Management LLC's cost basis in ELVN?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.